IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
Read More
Tag: IBSA
- Tremfya data show sustained remission in ulcerative colitis through 3 years
- Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
